Replies to post #21930 on NorthWest Biotherapeutics Inc (NWBO)

[austinmediainc]

then you should also be aware that they finished enrollment and all manufacturing in 2012

From IMUC's 10K

From January 2011 until September 2012, the trial enrolled 278 patients at 25 centers throughout the U.S. and 124 patients were randomized to ICT-107 or placebo

Does it really matter, the point is that their R&D expenses even in the heart of a Phase II trial were significantly less than ours.
2012 R&D -$7,711,233
2011 R&D -$4,988,612

Manufacturing became the key DOWNFALL for Dendreon. If you think it is such a good idea for NWBO to take the manufacturing in house, just look at what happened to Dendreon when they did that. That decision was a big factor in Dendreon's commercial failure.

Wow, and you call me misleading? DNDN's downfall had to do with manufacturing yes, but it had absolutely nothing to do with the fact that it was "in-house". It had everything to do with the fact that it was tedious for doctors to initiate, ship, manufacture, store, and the shelf life of the product, not to mention it cost a fortune.

NWBO's processes are second generation, NWBO's not Cognate's. NWBO has made these process advancements and from what I can gather, which isn't much seeing the company refuses to address the situation, is that Cognate is simply the entity in which produces NWBO's proprietary treatment with NWBO's proprietary processes. So as Dennis Hopper said to Christopher Walken in True Romance......am I lying?